Carbamazepine in Ventricular Extrasystoles Management: Clinical Case
https://doi.org/10.15690/pf.v20i3.2574
Abstract
Carbamazepine is a drug that has been used for a long time to treat various neurological and psychiatric disorders. The drug has effect on many body systems and, in particular, on the cardiovascular. The cardiovascular effect of carbamazepine depends on several factors such as the presence/absence of any comorbidities and its plasma concentration. The drug’s antiarrhythmic effect was demonstrated previously in a number of experimental and clinical studies. In this article, we would like to present the clinical case of pediatric patient with frequent ventricular extrasystoles and arrhythmogenic myocardial dysfunction. Several antiarrhythmic drugs were ineffective in this patient, while carbamazepine administration contributed to the decrease in ectopic activity up to minimal values.
Keywords
carbamazepine,
ventricular extrasystole,
therapeutic drug monitoring,
arrhythmogenic myocardial dysfunction
Supporting agencies: Not specified
About the Authors
Leonid S. Gordeev
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
MD.
2 Lomonosovsky Ave., building 2, Moscow, 119296
Tel.: +7 (916) 066-53-65
Disclosure of interest:
Not declared
Ekaterina K. Kulbachinskaya
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
MD.
Moscow
Disclosure of interest:
Not declared
Vera V. Bereznitskaya
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
MD, PhD.
Moscow
Disclosure of interest:
Not declared
References
1. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Hardman GJ, Limbird LE, Godman Gilman A, et al., eds. 9th ed. New York: McGraw-Hill; 1996.
2. Makiyama T, Akao M, Tsuji K, et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol. 2005;46(11):2100-2006. doi: https://doi.org/10.1016/j.jacc.2005.08.043
3. Lifshitz M, Gavrilov V, Sofer S. Signs and symptoms of carbamazepine overdose in young children. Pediatr Emerg Care. 2000;16(1):26. doi: https://doi.org/10.1097/00006565-200002000-00008
4. Beerman B, Edhag O, Valin H. Advanced heart block aggravated by carbamazepine. Br Heart J. 1975;37(6):668-671. doi: https://doi.org/10.1136/hrt.37.6.668
5. Venugopalan P, Al-Anqoudi ZAM, Al-Maamari WSM. A child with supraventricular tachycardia and convulsions. Ann Trop Paediatr. 2003;23(1):79-82. doi: https://doi.org/10.1179/000349803125002913
6. Opherk C, Coromilas J, Hirsch LJ. Heart rate and EKG changes in 102 seizures: analysis of influencing factors. Epilepsy Res. 2002;52(2):117-127. doi: https://doi.org/10.1016/s0920-1211(02)00215-2
7. Gordeev LS, Kulbachinskaya EK, Bereznitskaya VV. Effects of Carbamazepine on Cardiovascular System: Literature Review. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2022;19(6):484-491. (In Russ). doi: https://doi.org/10.15690/pf.v19i6.2491
8. Honda Y, Li J, Hino A, et al. High-Throughput Drug Screening System Based on Human Induced Pluripotent Stem Cell-Derived Atrial Myocytes ~ A Novel Platform to Detect Cardiac Toxicity for Atrial Arrhythmias. Front Pharmacol. 2021;12:680618. doi: https://doi.org/10.3389/fphar.2021.680618
9. Kenneback G,Bergfeldt L, Tomson T. Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects. Cardiovasc Drugs Ther. 1995;9(5):709-714. doi: https://doi.org/10.1007/BF00878554
10. Kenneback G, Bergfeldt L, Vallin H, et al. Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J. 1991;121(5):1421-1429. doi: https://doi.org/10.1016/0002-8703(91)90148-b
Review
For citations:
Gordeev L.S., Kulbachinskaya E.K., Bereznitskaya V.V. Carbamazepine in Ventricular Extrasystoles Management: Clinical Case. Pediatric pharmacology. 2023;20(3):252-255. (In Russ.) https://doi.org/10.15690/pf.v20i3.2574
Views:
948
Email this article 